-
1 Comment
TriplePoint Venture Growth BDC Corp is currently in a long term uptrend where the price is trading 15.0% above its 200 day moving average.
From a valuation standpoint, the stock is 12.5% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 10.2.
TriplePoint Venture Growth BDC Corp's total revenue sank by 56.8% to $10M since the same quarter in the previous year.
Its net income has dropped by 15.6% to $5M since the same quarter in the previous year.
Finally, its free cash flow grew by 122.5% to $26M since the same quarter in the previous year.
Based on the above factors, TriplePoint Venture Growth BDC Corp gets an overall score of 2/5.
ISIN | US89677Y1001 |
---|---|
Exchange | NYSE |
CurrencyCode | USD |
Sector | Financial Services |
Industry | Asset Management |
Beta | 1.5 |
---|---|
Market Cap | 244M |
PE Ratio | 7.23 |
Target Price | 6.9583 |
Dividend Yield | 20.% |
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TPVG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025